close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
68 69 Next >
News headline image
Biotech Is Coming Back, Can The Run Last? ↗
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
News headline image
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Why CRISPR Stock Keeps Falling ↗
CRISPR just scored its first FDA victory -- but profits remain years away. 
Via The Motley Fool
News headline image
The Latest Analyst Ratings for Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Bull Of The Day: Crispr Therapeutics ↗
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
News headline image
Forget the "Magnificent Seven": Buy This Stock Instead ↗
It's hard to go wrong with this high-flying drugmaker. 
Via The Motley Fool
News headline image
Looking Into Vertex Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
News headline image
3 Unstoppable Stocks to Buy Right Now ↗
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? ↗
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
News headline image
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years ↗
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead. 
Via The Motley Fool
News headline image
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
News headline image
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review ↗
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment ↗
Crispr stock rose in early trades on Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment. 
Via Investor's Business Daily
News headline image
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
News headline image
Healthcare Gems: 3 Essential Long-Term Stock Picks ↗
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
News headline image
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics ↗
Shareholders will do well to prepare themselves for how regulators might react. 
Via The Motley Fool
News headline image
5 Unstoppable Trends to Invest $1,000 in for 2024 ↗
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year. 
Via The Motley Fool
News headline image
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
News headline image
Vertex Appoints Nancy Thornberry to its Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Better Growth Stock: CRISPR Therapeutics vs. Invitae ↗
One of these stocks may be riskier than the other... 
Via The Motley Fool
News headline image
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
News headline image
A Bull Market Is Coming. Here Are 3 Stocks You'll Absolutely Want to Own. ↗
These stocks are already big winners in 2023 and should keep their momentum going in a new bull market. 
Via The Motley Fool
News headline image
Where Will Vertex Pharmaceuticals Be in 10 Years? ↗
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
News headline image
3 No-Brainer Growth Stocks to Buy in December ↗
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
News headline image
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now ↗
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy Before 2024 ↗
These stocks have room to run -- next year and over the long term. 
Via The Motley Fool
News headline image
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
It's not as long a shot as some might think. 
Via The Motley Fool
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today